# Safety Assessment of T4090 Eye Drops in Ocular Hypertensive or Glaucomatous Patients.

> **NCT05389267** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Laboratoires Thea** · enrollment: 120 (estimated)

## Conditions studied

- Glaucoma
- Ocular Hypertension

## Interventions

- **DRUG:** Kinezodianone R hydrochloride
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05389267
- **Lead sponsor:** Laboratoires Thea
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-07-05
- **Primary completion:** 2024-12-31
- **Final completion:** 2024-12-31
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2024-02-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05389267

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05389267, "Safety Assessment of T4090 Eye Drops in Ocular Hypertensive or Glaucomatous Patients.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05389267. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*